扩散加权与对比增强MRI监测乳腺癌新辅助治疗反应的比较
该研究纳入2015至2018年间接受新辅助治疗(NAT)后行3.0-T MRI检查并手术的1062例乳腺癌患者,比较扩散加权MRI(DW-MRI)与对比增强MRI(CE-MRI)预测病理完全缓解(pCR)的灵敏度及测量残余肿瘤大小的 agreement。结果显示两者预测pCR的灵敏度无显著差异(65.3% vs 62.9%,p=0.50),与病理测量残余肿瘤大小的组内相关系数(ICC)亦无显著差异(CE-MRI 0.62 vs DW-MRI 0.64,p=0.49);预测pCR的最佳ADC阈值为1.22×10^-3 mm2/s,AUC为0.73(95%CI 0.68-0.78)。作者认为DW-MRI可作为CE-MRI的替代或补充技术用于评估NAT反应。
要点
- DW-MRI与CE-MRI预测pCR的灵敏度无显著差异(65.3% vs 62.9%,p=0.50)。
- DW-MRI与CE-MRI测量残余肿瘤大小与病理的一致性无显著差异(ICC 0.64 vs 0.62,p=0.49)。
- 预测pCR的最佳ADC阈值为1.22×10^-3 mm2/s,AUC为0.73(95%CI 0.68-0.78)。
核心结论
- DW-MRI预测pCR的灵敏度及测量残余浸润性肿瘤大小与病理的一致性均与CE-MRI相当。
- ADC可作为区分残余肿瘤与治疗后改变的附加工具。
- 作者认为DW-MRI可能作为CE-MRI的替代或补充技术用于评估乳腺癌患者对NAT的反应。
研究设计与样本
- 研究为评估DW-MRI与CE-MRI预测乳腺癌NAT后肿瘤反应诊断性能的对照研究,纳入2015至2018年间接受NAT后行3.0-T MRI检查并手术的乳腺癌患者1062例(年龄49.3岁±9.0)。
- 使用CE-MRI和b值为0和1000 s/mm2的DW-MRI对NAT后pCR及残余肿瘤大小进行定性评估。
- 以手术病理为参考标准,比较CE-MRI、DW-MRI与病理的残余肿瘤大小一致性,并在残余高信号病灶中用Youden指数估计预测pCR的ADC截断值。
诊断标准与关键数值
- DW-MRI预测pCR的灵敏度为62.9%,CE-MRI为65.3%,两者无显著差异(p=0.50)。
- CE-MRI与病理测量残余肿瘤大小的ICC为0.62(95%CI 0.58-0.66),DW-MRI与病理的ICC为0.64(95%CI 0.61-0.68),两者无显著差异(p=0.49)。
- 预测pCR的最佳ADC截断值为1.22×10^-3 mm2/s,AUC为0.73(95%CI 0.68-0.78)。
- HR+/HER2-亚型的阳性预测值显著低于其他亚型,阴性预测值显著高于其他亚型。
- 残余肿瘤大小在HR+/HER2-亚型中被低估,在HR-/HER2+亚型中被高估。
临床应用与阅片要点
- DW-MRI预测pCR的灵敏度及测量残余肿瘤大小与病理的一致性均与CE-MRI相当,ADC可作为区分残余肿瘤与治疗后改变的附加工具。
- HR+/HER2-亚型阳性预测值较低、阴性预测值较高,且残余肿瘤大小被低估,阅片时需结合亚型解读。
- HR-/HER2+亚型残余肿瘤大小被高估,报告时应考虑亚型对大小评估的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic performance of post-neoadjuvant therapy (NAT) diffusion-weighted magnetic resonance imaging (DW-MRI) compared to contrast-enhanced MRI (CE-MRI) in predicting tumor response in breast cancer.
MATERIALS AND METHODS: Patients with breast cancer who were examined using 3.0-T MRI after NAT and underwent surgery between 2015 and 2018 were studied. Qualitative assessment of pathological complete response (pCR) and size of residual tumor following NAT were evaluated using CE-MRI and DW-MRI with b-values of 0 and 1000 s/mm2. Apparent diffusion coefficient (ADC) cut-off for predicting pCR was estimated using Youden's Index in lesions with residual high signal intensity. Agreement of residual tumor size at CE-MRI, DW-MRI, and pathology was compared.
RESULTS: A total of 1062 patients (49.3 years ± 9.0) were evaluated. Sensitivity for predicting pCR did not show a significant difference between CE-MRI and DW-MRI (65.3% and 62.9%, p = 0.50). The HR+/HER2- subtype showed significantly lower positive predictive value and higher negative predictive value than the others. Agreement of residual tumor size between CE-MRI and pathology (intraclass correlation coefficient [ICC], 0.62; 95% confidence interval [CI]: 0.58-0.66) and between DW-MRI and pathology (ICC, 0.64; 95% CI: 0.61-0.68) did not differ significantly (p = 0.49). Residual tumor size was underestimated in the HR+/HER2- subtype and overestimated in the HR-/HER2+ subtype. The optimum ADC cut-off was 1.22 × 10-3 mm2/s, with the area under the curve of 0.73 (95% CI: 0.68-0.78).
CONCLUSION: DW-MRI demonstrated comparable sensitivity for predicting pCR and agreement in residual invasive tumor size measurement to CE-MRI. ADC can be used as an additional tool for distinguishing residual tumors from post-treatment changes.
KEY POINTS: Question The effectiveness of diffusion-weighted MRI in predicting tumor response to NAT in breast cancer remains uncertain. Findings Diffusion-weighted MRI demonstrated similar sensitivity to CE-MRI in predicting pCR and comparable accuracy in measuring residual tumor size. Clinical relevance Diffusion-weighted MRI could potentially be used as an alternative or complementary technique to CE-MRI for evaluating tumor response to NAT in patients with breast cancer.
引用
- Eom HJ, Kim HH, Kim HJ, et al. Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer. Eur Radiol. 2025. PMID: 40555802. doi:10.1007/s00330-025-11640-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。